Trial results

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

NCT07374445 on ClinicalTrials.gov · last registry update 2026-01-28

Finished 1 June 2025, after enrolling 100 people. Primary outcome, as filed: Change in %TWL from baseline to endpoint across patient groups. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P4

Drug

liraglutide

Victoza, Xultophy, Saxenda

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Sponsor type

Other

Enrollment

100

Started

2023-09-01

Primary completion

2025-06-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in %TWL from baseline to endpoint across patient groups

Conditions studied

Obesity · Weight Loss · Bariatric Surgery

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.